CIK 0001849296 · Non-accelerated filer<br>Emerging growth company
OKYO Pharma Ltd
Sign in to watch- Ticker
- OKYO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- Entity type
- other
- Phone
- 44 (0) 207 495 2379
- Business address
- 55 PARK LANE, LONDON, United Kingdom, W1K 1NA
- 6-K Event Report of Foreign Issuer
- 6-K Event Report of Foreign Issuer
- 6-K Event Report of Foreign Issuer
- 6-K Event Report of Foreign Issuer
- 6-K Event Report of Foreign Issuer
- 6-K Event Report of Foreign Issuer
- 20-F/A Report Annual and Transition Report of Foreign Private Issuers
- 4/A Open-market buy Director bought 5,000 shares at $1.48 ($7,385)
- 4/A Open-market buy CHIEF EXECUTIVE OFFICER bought 15,000 shares at $1.54 ($23,085)
- 4/A Open-market buy CHIEF DEVELOPMENT OFFICER bought 3,500 shares at $1.40 ($4,900)
- 4/A Open-market buy Director bought 22,500 shares at $1.45 ($32,625)
- 4/A Open-market buy Director bought 25,000 shares at $1.40 ($35,000)
- 4/A Open-market buy CHIEF MEDICAL OFFICER bought 20,000 shares at $1.40 ($28,000)
- 4/A Open-market buy Chief Scientific Officer bought 3,363 shares at $1.49 ($5,011)
- 4 Grant or award Chief Scientific Officer acquired 3,363 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 6-K Event Report of Foreign Issuer
- 6-K Event Report of Foreign Issuer
- 4 Grant or award CHIEF EXECUTIVE OFFICER acquired 15,000 shares (grant or award)
- 4 Grant or award Director acquired 22,500 shares (grant or award)
Page 1 of 16 · 312 filings